Disparities in health care access may influence the likelihood of initiating antidepressant medications after COVID-19 exposure.

Amyloid-related imaging abnormality occurs for nearly 1 in 4 patients treated with lecanemab for MCI or mild AD with confirmed amyloid pathology.

Nearly 4 in 10 inpatient psychiatric mental health registered nurses (PMH-RNs) experience high burnout, according to a study published online July 27 in the Jou ...

Dr Erica Schwartz will lead the CDC following a recent confirmation vote in the Senate confirming her appointment as head of the agency.

Genome-wide association data reveals a shared genetic foundation between schizophrenia and the use of specific prescription medications.

A recent review highlights the neurophysical changes associated with immersive virtual reality-induced hypoalgesia for pain management.

Hilary L. Colbeth, Ph.D., from the University of California (UC) Davis, and colleagues examined dementia incidence and its risk factors in people older than 90 years as part of the LifeAfter90 study.

The FDA has approved Orzeyful (oveporexton), a first-in-class oral orexin receptor 2 agonist, for the treatment of adult narcolepsy type 1.

As autism therapy utilization and spending expand rapidly, federal agencies are pushing for state oversight to manage Medicaid budget policy.

SAD shares genetic risk with several psychiatric illnesses, but these factors are not linked to common clinical subtypes, such as severity or comorbid MDD.

Anxiety symptoms appear to be common among a portion of patients with chronic rhinosinusitis with nasal polyps.

FDA grants Fast Track designation to PVX108, a novel peptide immunotherapy for peanut allergy, supported by phase 1 data and an ongoing phase 2 pediatric trial.